Gain Therapeutics, Inc.

Gain Therapeutics (GANX) has reported zero cyber incidents and zero red-flag 8-K filings over the past 90 days, indicating no immediate corporate governance crises in our ingestion window. However, low signal in a short timeframe does not exclude material risks; a biotech firm's viability depends on financing runway, shareholder dilution trajectory, and pipeline execution probability. The full $49 Report extends analysis to 12 months of SEC filings, calculates dilution risk score, maps capital raise history, and flags AI-detected stress signals in MD&A language that plain filings often obscure. The full $49 Report adds quantified dilution exposure, 12-month event context, and forward risk scoring.